ArticleCureus2026
Behavioral Effects of Renin-Angiotensin System Modulators in a Rotenone-Induced Model of Parkinson's Disease in Wistar Albino Rats.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor dysfunction resulting from dopaminergic neuronal loss. Emerging evidence suggests a role of the renin-angiotensin system (RAS) in neurodegeneration, making it a potential therapeutic target. The present study aimed to evaluate the behavioral effects of captopril, perindopril, and losartan on motor, behavioral, and anxiety parameters in a rotenone-induced model of Parkinson's disease in Wistar albino rats. MATERIALS AND
methodsAn experimental in vivo study was conducted using a rotenone-induced PD model in Wistar albino rats (n = 6 per group). Animals were divided into six groups: vehicle control, rotenone control, standard treatment group (levodopa + benserazide), and treatment groups receiving captopril, perindopril, or losartan along with rotenone. Neurobehavioral assessments included locomotor activity, rotarod performance, wire-hanging test, hole board test, forced swim test, and elevated plus maze. Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test.
resultsRotenone administration significantly impaired motor and behavioral parameters, with reduced locomotor activity (18.67 ± 4.11 vs 174.33 ± 25.01 counts/10 min), rotarod performance (10.17 ± 1.19 vs 118.17 ± 1.83 sec), and wire-hanging performance (8.83 ± 1.80 vs 116.33 ± 3.67 sec), along with increased immobility-related and anxiety-like behavioral changes (P < 0.001). Treatment with captopril, perindopril, and losartan significantly improved motor performance and behavioral outcomes, with locomotor activity ranging from 141.83 to 154.50 counts/10 min and rotarod performance from 108.67 to 114.17 sec. Significant reductions in immobility time and improvements in exploratory and anxiety-related parameters were also observed (P < 0.001).
conclusionRAS modulation using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers demonstrated significant improvement in motor and behavioral parameters in a rotenone-induced PD model. These findings suggest the potential therapeutic utility of these agents in mitigating both motor and non-motor manifestations associated with PD. However, further biochemical, histopathological, mechanistic, and clinical investigations are required to establish their potential neuroprotective role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.